A recent study of FLT3 testing behavior in relapsed acute myeloid leukemia (AML) conducted by experts at Diaceutics has uncovered the need for faster laboratory testing turnaround times (TAT). CTO at Diaceutics, Jordan Clark discussed the findings with OncLiveL1 at this year’s EHA Congress where the abstract was accepted for publication. The abstract analyzes the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. Read the full abstract hereL2
Link References
1. OncLive
2. here
